divalproex sodium ER

ApprovedSmall molecule

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

divalproex sodium ER is one of 139 small molecule programs targeting Schizoaffective Disorder. It is currently in Approved.

Indications

Total Trials

Active Trials

138

Competitors

Pipeline

Status by Indication[3][1]

Indication

Schizoaffective DisorderActive, not recruiting

Bipolar DisorderActive, not recruiting

AutismActive, not recruiting

Schizoaffective DisorderPhase 1

Active, not recruiting

Bipolar DisorderApproved

Active, not recruiting

AutismApproved

Active, not recruiting

Competition

Competitive Landscape

192 competitors in Bipolar Disorder

#DrugCompanyPhaseTrials

Depacon

AbbVie

Phase 3

6 2

Depakote

AbbVie

Phase 3

5 3

Depakote

AbbVie

Phase 3

5 4

Robitussin

Pfizer

Phase 3

2 5

Lexapro

AbbVie

Phase 3

2 6

Paxil

SSebela Pharmaceuticals Development LLC

Phase 3

3 7

Ketalar

Boehringer Ingelheim

Phase 3

2 8

Methylthioninium Chloride

PProvepharm SAS

Phase 3

1 9

Rescue

Merck & Co.

Phase 3

2 10

Nolvadex

SSan Diego Pacific Oncology & Hematology Associates

Phase 3

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Interaction2 trials

A Drug Interaction Study of Valproic Acid and Single-dose Paliperidone Extended-Release (ER) in Healthy Men

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 1·NCT01060228·24 enrolled

Drug-Drug Interaction Study to Evaluate the Effect of Inhibition of UGTs on the PK of Ecopipam and Its Active Metabolite

Completed·EEmalex Biosciences Inc.·Phase 1·NCT04902105·38 enrolled

Bipolar Disorder2 trials

Divalproex ER vs. Risperidone for Bipolar Disorder With Comorbid Substance Use Disorder

Completed·TTuscaloosa Research & Education Advancement Corporation·Phase 4·NCT00203528·30 enrolled

Quetiapine SR and Divalproex Sodium ER in the Treatment of Anxiety in Bipolar Disorder With Panic Disorder and/or GAD

Completed·UUniversity of South Florida·Phase 4·NCT00579280·224 enrolled

Autism1 trial

Divalproex Sodium ER in Adult Autism

Completed·MMontefiore Medical Center·Phase 4·NCT00211796·10 enrolled

Double-blind1 trial

Double-blind, Placebo-Controlled Divalproex Sodium ER in Bipolar I or Bipolar II Depression

Completed·UUniversity Hospitals Cleveland Medical Center·Phase 3·NCT00194116·54 enrolled

Schizoaffective Disorder1 trial

A Drug Interaction Study of Valproic Acid and Paliperidone Extended-Release (ER) in Patients With Schizophrenia, Bipolar I Disorder, or Schizoaffective Disorder

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 1·NCT01094249·9 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for divalproex sodium ER. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — divalproex sodium ER compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for divalproex sodium ER. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Johnson & Johnson Pharmaceutical Research & Development, L.L.C. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

divalproex sodium ER

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Interaction2 trials

Bipolar Disorder2 trials

Autism1 trial

Double-blind1 trial

Schizoaffective Disorder1 trial

References

Drug Info

Quick Facts

Related News